While $5.7 billion was invested in companies developing cellular and genetic therapies, and with 800 clinical trials initiated worldwide and the first two CAR-T cell therapies expected to launch into market later this year, businesses still say the ability to get these treatments to patients is limited by paperwork, supply chain management, and last mile delivery. Read Morevia Zero Tech Blog
